Stockscreener 앱 받기
0.26
2.84%
-0.0076
시간 외 거래:
.26
전일 마감가:
$0.2676
열려 있는:
$0.27
하루 거래량:
1.03M
Relative Volume:
0.27
시가총액:
$11.54M
수익:
$1.04M
순이익/손실:
$-67.50M
주가수익비율:
-0.1353
EPS:
-1.9222
순현금흐름:
$-60.67M
1주 성능:
-1.44%
1개월 성능:
+13.44%
6개월 성능:
-50.94%
1년 성능:
-92.15%
1일 변동 폭
$0.2573
$0.27
1주일 범위
$0.2511
$0.2765
52주 변동 폭
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.26 | 11.88M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics Releases Q1 2027 Financial Results - news.alphastreet.com
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026 - TradingView
Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data - Stock Titan
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - GlobeNewswire
Press Release: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
VistaGen Granted Nasdaq Extension to Regain Bid Compliance - The Globe and Mail
Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals - Stock Titan
Vistagen (VTGN) Reports Phase 2 Social Anxiety Study Results Ami - GuruFocus
Vistagen reports phase 2 social anxiety trial results - Investing.com
Vistagen's second fasedienol dose showed no new safety findings - Stock Titan
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension - Stock Titan
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - financialcontent.com
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics - TipRanks
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics - finance.yahoo.com
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG - The National Law Review
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
SRX Global Acquires Stake in Vistagen Therapeutics - Yahoo Finance
SRX Global Inc. Acquires Undisclosed Stake in Vistagen Therapeutics - citybiz
Press Release: SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - Moomoo
SRX Global acquires Vistagen stake, terms undisclosed - grafa.com
SRX Global (NYSE American: SRXH) Acquires Stake In Vistagen Therapeutics - Menafn
SRX Global acquires stake in Vistagen Therapeutics - Bitget
Vistagen Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
VTGN FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages V - The National Law Review
VistaGen Therapeutics Appoints Douglas Williamson to Board - The Globe and Mail
Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
Vistagen appoints Douglas Williamson to board of directors By Investing.com - Investing.com Nigeria
Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board - Stock Titan
Vistagen Appoints Douglas J. Williamson to its Board of Directors - GlobeNewswire
Vistagen appoints Douglas Williamson to board of directors - Investing.com
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics, Inc. Revenue Breakdown – BMV:VTGN - TradingView
TradingKey - TradingKey
VTGN|Vistagen Therapeutics Inc|Price:0.226|Chg%:+0.000 - TradingKey
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance
VTGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTGN Stockholders Have Opportunity to Lead Vistagen Therapeutics - The National Law Review
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
1.77%
자본화:
|
볼륨(24시간):